Clinical Characteristics and Outcomes of COVID-19 in Turkish Patients with Hematological Malignancies
Tarih
2022Yazar
TERZİ, HATİCE
TOPRAK, SELAMİ KOÇAK
Goksoy, Hasan Sami
Aydin, Berrin Balik
DEMİRCİ, UFUK
Can, Ferda
ÖZKOCAMAN, VİLDAN
GÜNDÜZ, EREN
GÜVEN, ZEYNEP TUĞBA
ÖZKURT, ZÜBEYDE NUR
Demircioglu, Sinan
BEKSAÇ, MERAL
Ince, Idris
YILMAZ, UMUT
Kucukdiler, Hilal Eroglu
Abishov, Elgun
YAVUZ, BORAN
Atas, Unal
Mutlu, Yasa Gul
Bekoz, Huseyin Saffet
AKSU, TEKİN
Maral, Senem
Erol, Veysel
KAYNAR, LEYLAGÜL
İLHAN, OSMAN
BOLAMAN, ALİ ZAHİT
Sevindik, Omur Gokmen
AKYAY, ARZU
ÖZCAN, MUHİT
GÜRMAN, GÜNHAN
ÜNAL CANGÜL, ŞULE
YAVUZ, YASEMİN
Kucukkaya, Reyhan Diz
ÖZSAN, GÜNER HAYRİ
ÇENELİ, ÖZCAN
Abbasov, Hamza
Selim, Cem
AR, MUHLİS CEM
CİVRİZ BOZDAĞ, SİNEM
BAŞ, VOLKAN
ÖZKALEMKAŞ, FAHİR
ÜSKÜDAR TEKE, HAVA
Gursoy, Vildan
ÇELİK, SERHAT
Ciftciler, Rafiye
Yagci, Munci
TOPÇUOĞLU, PERVİN
YÜCEL, ORHAN KEMAL
Sadri, Sevil
ALBAYRAK, CANAN
DEMİR, AHMET MUZAFFER
Guler, Nil
KEKLİK, MUZAFFER
Dogan, Ali
YEGİN, ZEYNEP ARZU
YÜKSEL, MELTEM
Sadri, Sogol
YAVAŞOĞLU, İRFAN
CENGİZ SEVAL, GÜLDANE
Hindilerden, Ipek Yonal
Hindilerden, Fehmi
ANDIÇ, NESLİHAN
BAYDAR, MUSTAFA
AYDIN KAYNAR, LALE
Üst veri
Tüm öğe kaydını gösterÖzet
Objective: Patients with solid malignancies are more vulnerable to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection than the healthy population. The outcome of SARS-CoV-2 infection in highly immunosuppressed populations, such as in patients with hematological malignancies, is a point of interest. We aimed to analyze the symptoms, complications, intensive care unit admissions, and mortality rates of patients with hematological malignancies infected with SARS-CoV-2 in Turkey. Materials and Methods: In this multicenter study, we included 340 adult and pediatric patients diagnosed with SARS-CoV-2 from March to November 2020. Diagnosis and status of primary disease, treatment schedules for hematological malignancies, time from last treatment, life expectancy related to the hematological disease, and comorbidities were recorded, together with data regarding symptoms, treatment, and outcome of SARS-CoV-2 infection. Results: Forty four patients were asymptomatic at diagnosis of SARSCoV-2 infection. Among symptomatic patients, fever, cough, and dyspnea were observed in 62.6%, 48.8%, and 41.8%, respectively. Sixtynine (20%) patients had mild SARS-CoV-2 disease, whereas moderate, severe, and critical disease was reported in 101 (29%), 71 (20%), and 55 (16%) patients, respectively. Of the entire cohort, 251 (73.8%) patients were hospitalized for SARS-CoV-2. Mortality related to SARS-CoV-2 infection was 26.5% in the entire cohort; this comprised 4.4% of those patients with mild disease, 12.4% of those with moderate disease, and 83% of those with severe or critical disease. Active hematological disease, lower life expectancy related to primary hematological disease, neutropenia at diagnosis of SARS-CoV-2, ICU admission, and first-line therapy used for coronavirus disease-2019 treatment were found to be related to higher mortality rates. Treatments with hydroxychloroquine alone or in combination with azithromycin were associated with a higher rate of mortality in comparison to favipiravir use. Conclusion: Patients with hematological malignancy infected with SARS-CoV-2 have an increased risk of severe disease and mortality.
Bağlantı
http://hdl.handle.net/20.500.12627/183515https://avesis.istanbul.edu.tr/api/publication/82513f28-7a67-4796-aeda-6d220d3d7f2b/file
https://doi.org/10.4274/tjh.galenos.2021.2021.0287
Koleksiyonlar
- Makale [2276]